The project
Target Specific Delivery of Optimized RNA Therapeutics for the Treatment of Pediatric Sarcomas
PCF's published Our Impact description, checked September 15, 2026. Planned trial, enrollment and site language below is source wording, not a current trial-status update.
This project develops a targeted delivery system to restore the cancer-fighting protein p53 by blocking MDM2, aiming to improve treatment and survival for children with aggressive rhabdomyosarcoma.